Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $523.33 million. The enterprise value is $314.86 million.
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 382.00 million shares outstanding. The number of shares has increased by 82.38% in one year.
| Current Share Class | 382.00M |
| Shares Outstanding | 382.00M |
| Shares Change (YoY) | +82.38% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 1.53% |
| Owned by Institutions (%) | 47.39% |
| Float | 239.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.99 |
| Forward PS | 6.71 |
| PB Ratio | 1.23 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.16, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.16 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -96.06 |
Financial Efficiency
Return on equity (ROE) is -29.54% and return on invested capital (ROIC) is -16.36%.
| Return on Equity (ROE) | -29.54% |
| Return on Assets (ROA) | -13.62% |
| Return on Invested Capital (ROIC) | -16.36% |
| Return on Capital Employed (ROCE) | -30.06% |
| Revenue Per Employee | $210,600 |
| Profits Per Employee | -$147,313 |
| Employee Count | 818 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 2.63 |
Taxes
| Income Tax | -307,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.50% in the last 52 weeks. The beta is 1.29, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -33.50% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.35 |
| Relative Strength Index (RSI) | 58.12 |
| Average Volume (20 Days) | 1,189,626 |
Short Selling Information
The latest short interest is 12.17 million, so 3.19% of the outstanding shares have been sold short.
| Short Interest | 12.17M |
| Short Previous Month | 12.54M |
| Short % of Shares Out | 3.19% |
| Short % of Float | 5.07% |
| Short Ratio (days to cover) | 9.99 |
Income Statement
In the last 12 months, LAB had revenue of $172.27 million and -$120.50 million in losses. Loss per share was -$0.32.
| Revenue | 172.27M |
| Gross Profit | 84.54M |
| Operating Income | -137.94M |
| Pretax Income | -118.58M |
| Net Income | -120.50M |
| EBITDA | -121.81M |
| EBIT | -137.94M |
| Loss Per Share | -$0.32 |
Full Income StatementBalance Sheet
The company has $237.09 million in cash and $28.62 million in debt, giving a net cash position of $208.47 million or $0.55 per share.
| Cash & Cash Equivalents | 237.09M |
| Total Debt | 28.62M |
| Net Cash | 208.47M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 424.54M |
| Book Value Per Share | 1.11 |
| Working Capital | 408.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$92.88 million and capital expenditures -$12.58 million, giving a free cash flow of -$105.46 million.
| Operating Cash Flow | -92.88M |
| Capital Expenditures | -12.58M |
| Free Cash Flow | -105.46M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
Gross margin is 49.07%, with operating and profit margins of -80.07% and -69.95%.
| Gross Margin | 49.07% |
| Operating Margin | -80.07% |
| Pretax Margin | -80.33% |
| Profit Margin | -69.95% |
| EBITDA Margin | -70.71% |
| EBIT Margin | -80.07% |
| FCF Margin | n/a |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -82.38% |
| Shareholder Yield | -82.38% |
| Earnings Yield | -23.03% |
| FCF Yield | -20.15% |
Analyst Forecast
The average price target for LAB is $2.50, which is 82.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.50 |
| Price Target Difference | 82.48% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -15.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of -0.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.07 |
| Piotroski F-Score | 3 |
